Posted by Michael Wonder on 24 Jun 2022
Astellas submits fezolinetant new drug application to U.S. FDA
24 June 2022 - Application targets treatment of moderate to severe vasomotor symptoms associated with menopause
Astellas Pharma today announced a new drug application for fezolinetant has been submitted to the U.S. FDA.
